Kiniksa Pharmaceuticals, Ltd. (KNSA)
NASDAQ: KNSA · IEX Real-Time Price · USD
+0.02 (0.11%)
Apr 16, 2024, 4:00 PM EDT - Market closed

Company Description

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide.

Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.

The company was incorporated in 2015 and is based in Hamilton, Bermuda.

Kiniksa Pharmaceuticals, Ltd.
Kiniksa Pharmaceuticals logo
Country Bermuda
Founded 2015
IPO Date May 24, 2018
Industry Biotechnology
Sector Healthcare
Employees 297
CEO Sanj K. Patel

Contact Details

Clarendon House, 2 Church Street
Hamilton, D0 HM11
Phone 7814399100

Stock Details

Ticker Symbol KNSA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001730430
CUSIP Number G5269C101
ISIN Number BMG5269C1010
SIC Code 2834

Key Executives

Name Position
Sanj K. Patel Chief Executive Officer and Chairman of the Board
Eben Tessari Senior Vice President and Chief Operating Officer
Dr. John F. Paolini Senior Vice President and Chief Medical Officer
Mark Ragosa C.F.A. Senior Vice President and Chief Financial Officer
Michael R. Megna CPA Chief Accounting Officer and Group Vice President of Finance
Mei Jang Senior Vice President of Technical Operations
Rachel Frank Associate Director of Investor Relations
Chad Morin Senior Vice President and Chief Compliance Officer
Madelyn Demsky Zeylikman SVice President, General Counsel and Secretary
Melissa Manno Senior Vice President and Chief Human Resources Officer

Latest SEC Filings

Date Type Title
Apr 10, 2024 PRE 14A Other preliminary proxy statements
Apr 5, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Apr 2, 2024 8-K Current Report
Mar 29, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Mar 29, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Mar 29, 2024 8-K Current Report
Mar 4, 2024 144 Filing
Mar 1, 2024 144 Filing
Feb 28, 2024 S-8 Securities to be offered to employees in employee benefit plans
Feb 28, 2024 144 Filing